Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Infante

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Revista Espanola De Medicina Nuclear E Imagen Molecular|July 9, 2011
Coexistence of two different types of lymphoma in a patient with Sjögren's syndrome. The usefulness of the PET-CTJ R Infante De La Torre, C Durán Barquero, L García Bernardo, et al.
British Journal of Cancer|May 8, 2014
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignanciesA R Tan, A Dowlati, M N Stein, et al.
Revista Espanola De Medicina Nuclear|May 14, 2010
[Radioguided surgery of intestinal carcinoid tumor relapse. Role of SPECT-CT]J Serrano Vicente, M L Domínguez Grande, J R Infante De La Torre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2014
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumorsS Pant, M Saleh, J Bendell, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsJ R Infante, R Kurzrock, J Spratlin, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|March 1, 2023
PERCIST and Hopkins criteria and PET/CT metabolic parameters as prognostic factors in squamous head and neck cancerÁ Baena García, J R Infante de la Torre, R Barco Carbonero, et al.
Revista Espanola De Medicina Nuclear|February 24, 2009
[Negative predictive value of (123)I Ioflupane SPECT in movement disorders]J Serrano Vicente, L García Bernardo, C Durán Barquero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
Revista Espanola De Medicina Nuclear|December 18, 2009
[Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation]J Serrano Vicente, J R Infante de la Torre, M L Domínguez Grande, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Revista Espanola De Medicina Nuclear E Imagen Molecular|July 9, 2011
Coexistence of two different types of lymphoma in a patient with Sjögren's syndrome. The usefulness of the PET-CTJ R Infante De La Torre, C Durán Barquero, L García Bernardo, et al.
British Journal of Cancer|May 8, 2014
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignanciesA R Tan, A Dowlati, M N Stein, et al.
Revista Espanola De Medicina Nuclear|May 14, 2010
[Radioguided surgery of intestinal carcinoid tumor relapse. Role of SPECT-CT]J Serrano Vicente, M L Domínguez Grande, J R Infante De La Torre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2014
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumorsS Pant, M Saleh, J Bendell, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsJ R Infante, R Kurzrock, J Spratlin, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|March 1, 2023
PERCIST and Hopkins criteria and PET/CT metabolic parameters as prognostic factors in squamous head and neck cancerÁ Baena García, J R Infante de la Torre, R Barco Carbonero, et al.
Revista Espanola De Medicina Nuclear|February 24, 2009
[Negative predictive value of (123)I Ioflupane SPECT in movement disorders]J Serrano Vicente, L García Bernardo, C Durán Barquero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
Revista Espanola De Medicina Nuclear|December 18, 2009
[Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation]J Serrano Vicente, J R Infante de la Torre, M L Domínguez Grande, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
Pageof 6